Table 2.
Diagnostic efficiency of different combinations of serum bone biomarkers to distinguish lung cancer patients with bone metastasis from those without bone involvement
| Sensitivity | Specificity | Diagnostic | ||||
|---|---|---|---|---|---|---|
| Combination | AUC | 95% CI | % | % | P value | accuracy (%) |
| BME cytokines | ||||||
| CaN+IL-6 | 0.804 | 0.743–0.856 | 60.26 | 84.25 | < 0.001 | 75.12 |
| CaN+IL-6 + OPG | 0.847 | 0.790–0.893 | 74.36 | 84.25 | < 0.001 | 80.49 |
| CaN+IL-6 + OPG + PTHrP | 0.898 | 0.848–0.936 | 79.49 | 89.76 | < 0.001 | 85.63 |
| Bone turnover markers | ||||||
| tP1NP + β-CTx | 0.851 | 0.794–0.897 | 71.79 | 78.74 | < 0.001 | 76.1 |
| Independent diagnostic risk factors | ||||||
| OPG + PTHrP | 0.893 | 0.842–0.931 | 78.21 | 90.55 | < 0.001 | 76.1 |
| OPG + PTHrP+tP1NP | 0.924 | 0.864–0.952 | 81.69 | 84.47 | < 0.001 | 83.91 |
| OPG + PTHrP+tP1NP + β-CTx | 0.94 | 0.898–0.968 | 84.62 | 88.98 | < 0.001 | 87.32 |